Pan-European transplantation society connecting clinical networks to research in organ rejection, cell therapy, and precision transplant diagnostics.
ESOT is the pan-European professional society representing transplant physicians, surgeons, and scientists across Europe. Their core work centres on advancing clinical transplantation through education, guidelines, and clinical registry access, while serving as a network bridge connecting academic research teams with the European transplant clinical community. In H2020 projects they contribute clinical expertise, patient population access, and dissemination channels to research consortia working on improving transplant outcomes. Their European-wide membership makes them a key partner for validating and scaling transplantation-related innovations in real clinical settings.
Both EU-TRAIN and VANGUARD are grounded in transplantation medicine — EU-TRAIN targets kidney allograft rejection risk prediction, while VANGUARD addresses pancreatic cell transplantation as an alternative to organ replacement.
EU-TRAIN applies integrative epidemiology, gene expression profiling, and multidimensional smart data analysis to improve precision diagnosis and risk stratification of kidney allograft rejection.
VANGUARD involves bioartificial pancreas development using organoids, amniotic membranes, hydrogels, and CRISPR-Cas9 genome editing — a significant technological step beyond conventional transplantation practice.
Immunomodulation features explicitly in VANGUARD, while rejection risk management in EU-TRAIN both reflect ESOT's deep grounding in the immunological challenges of organ transplantation.
In their first H2020 project (EU-TRAIN, 2018), ESOT's focus was on data-driven precision medicine: using biomarkers, gene expression, and smart data integration to better predict and diagnose kidney allograft rejection — a clinically urgent but incremental improvement on existing transplant care. By 2020, with VANGUARD, the focus shifted toward regenerative and cell-based therapies — bioartificial pancreas construction using organoids, CRISPR-Cas9 genome editing, and tissue engineering approaches that could eventually reduce dependence on traditional organ donation altogether. This represents a meaningful strategic evolution: from managing transplant failures more precisely, toward engineering biological replacements that may one day prevent them.
ESOT is moving toward regenerative medicine and genome-edited cell therapies, suggesting future projects will sit at the intersection of transplantation and synthetic biology rather than classical clinical transplant management.
ESOT participates exclusively as a consortium partner rather than a project leader, which reflects their identity as a clinical network and knowledge disseminator rather than a research-executing body. They bring European-wide reach and clinical community access to research teams, rather than running laboratories or data infrastructure themselves. With 21 unique partners across 7 countries from just 2 projects, they engage in broad, geographically diverse consortia — the kind of large multi-partner RIA structures where a pan-European society provides clinical access and dissemination pathways that individual research groups cannot replicate.
ESOT has collaborated with 21 unique partners across 7 countries — a notably broad footprint for an organization with only 2 H2020 projects. Their actual network as a pan-European professional society, encompassing transplant clinicians, hospital centers, and researchers across member states, substantially exceeds what project participation data alone can capture.
Unlike research institutes or universities, ESOT is the professional home of Europe's transplant community — they provide direct access to clinicians, patient registries, and clinical validation networks that no single hospital or laboratory can match. For research consortia working on any transplantation-adjacent technology, ESOT's membership base translates directly into clinical adoption pathways and dissemination credibility across national health systems. Their value is not in conducting bench research but in ensuring that innovations actually reach the clinical transplant setting at European scale.
